AlphaStocks
6.2
Consider Buy

Charles River Laboratories International, Inc. (CRL)

As of Sep 20, 2026, Charles River Laboratories International, Inc. (CRL) scores 6.2/10 on AlphaStocks' five-model composite, #45 of 168 Health Care stocks. At $278, CRL trades 51% above its model fair value of $184.

Health Care / Life Sciences Tools & Services

S&P 500

$277.64

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#45out of 168 in Health Care

Is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. a Good Investment in 2026?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as Attractive (5/9). However, the Graham model rates it Caution. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. currently trades 51% above its estimated fair value of $184. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ranks #45 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-4.4Market Cap14B

Estimated Fair Value

$183.8851% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Neutral

Earnings yield 3.1% · ROC 21%

Frequently Asked Questions

Is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) a good investment?
As of Sep 20, 2026, Charles River Laboratories International, Inc. (CRL) scores 6.2/10 on AlphaStocks' five-model composite, #45 of 168 Health Care stocks. At $278, CRL trades 51% above its model fair value of $184. That is a middle-of-the-pack score with no strong signal either way.
What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Piotroski F-Score?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is CRL overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $184, CRL appears overvalued. The stock currently trades 51% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does CRL compare to other Health Care stocks?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ranks #45 out of 168 stocks in the Health Care sector, placing it in the top 27% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about CRL?
AlphaStocks evaluates CRL using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 6.2/10.

Similar Stocks

BIOILMNAZTA

Compare CRL with

BIO vs CRLCRL vs ILMNAZTA vs CRLCRL vs FTICRL vs PARR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer